Thomas Hartung, toxicology expert, predicts transformative role for AI in drug and chemical risk assessment at AAPS PharmSci 360

Written by AAPS

Toxicology expert Thomas Hartung, MD, PhD, of Johns Hopkins University (MD, USA) will present the opening plenary at AAPS PharmSci 360, Sunday, October 22 at 5 p.m. ET.

Dr Hartung’s presentation will emphasize artificial intelligence’s ability to harness extensive datasets and provide probabilistic outputs as key advantages that can facilitate more precise risk assessment approaches when compared to traditional methods.

Toxicology has shifted from a purely empirical science to a data-rich field ripe for AI integration, in Dr Hartung’s view. He forecasts a vital role for AI in transforming future drug and chemical risk assessments. He also believes AI methods are uniquely suited to handling the large, diverse data volumes central to modern toxicology.

“We are excited to have Dr Hartung provide the opening plenary presentation at PharmSci 360,” AAPS 2023 PharmSci 360 Scientific Programming Committee Chair Otilia Koo, PhD, said. “His talk will provide attendees with inspiration on how to develop new medicines faster through AI and harnessing big data.”

PharmSci 360 will take place October 22–25 in Orlando (FL, USA) at the Orange County Convention Center. To learn more and to register, visit www.aaps.org/pharmsci360


About AAPS

American Association of Pharmaceutical Scientists (AAPS) is a non-profit association of more than 7000 scientists and professionals employed in academia, industry, regulatory and other research related to the pharmaceutical sciences worldwide. Its mission is to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health, which members pursue through four peer-reviewed journals and a variety of events in person and online.